New weight loss injection enters human testing
NCT ID NCT06976372
Summary
This early-stage study tested a new injectable drug called AMG 133 in adults with overweight or obesity. The main goal was to understand how the drug moves through the body and to check its safety when given multiple times. Researchers enrolled 120 participants to receive different dosing schedules and monitored drug levels and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CenExel
Anaheim, California, 92801, United States
-
CenExel Collaborative Neuroscience Research, LLC Los Alamitos
Los Alamitos, California, 90720, United States
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247, United States
Conditions
Explore the condition pages connected to this study.